B+
Bull case
25%
Probability
Target price
$15.08
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
ARVN
ArvinasBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
ARVN has reached an important validation point with FDA approval of VEPPANU, a licensing arrangement with Rigel, and multiple clinical programs that could generate 2H26 data. The deterministic prior is positive, but the packet does not establish commercial uptake or clinical readout quality.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +14.5.
What can break
Cash-flow and financing runway visibility is insufficient in the supplied evidence.
Momentum
41
Value
41
Sentiment
76
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $9.09 · Bull $15.08 · Bear $5.50Analysis 2026-08-04; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-04 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $13.93
Why
Momentum41 · Δ7d -36.6
Value41 · Δ7d -0.0
Sentiment76 · Δ7d +14.5
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +14.5.
Contradictions & invalidation
- • Cash-flow and financing runway visibility is insufficient in the supplied evidence.
- • Clinical development, trial readout, regulatory, and execution risk across ARV-102, ARV-806, ARV-393, and ARV-027.
- • The stock remains highly dependent on execution across commercialization and clinical development.
Catalyst clock
2026-08-04
Q2 2026 results and corporate update
Lead driver: Sentiment · See AI snapshot
Momentum
41
9% active weight
Current posture
7d trendSoftening
Δ7d
-36.6
Δ21d
-4.2
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-17.7
Sentiment
76
62% active weight
Current posture
7d trendImproving
Δ7d
+14.5
Δ21d
+12.0
Why this grade
Composite grade B. Momentum 41.1 / Value 41.2 / Sentiment 75.8
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-04. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$9.09
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$5.50
Analysis reference price unavailable
Analysis 2026-08-04 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$601.55M
Beta
1.88
Shares Out
65.39M
P/E (TTM) · Derived
-8.1
P/S (TTM)
2.30
P/FCF (TTM) · Derived
-2.95
Rev YoY
+1014.7%
EPS YoY
-407.5%
Gross Margin
+95.6%
Op Margin
-4.0%
Net Debt
-$676.3M
Current Ratio
7.91
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data